SEC Form 4 · accession 0001437749-17-017238
Protagenic Therapeutics, Inc.\new · PTIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander K. Arrow
Officer — Chief Financial Officer
Period of report
Oct 16, 2017
Accepted (ET)
Oct 18, 2017 · 2:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001022899
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Options (Right to Buy)F1 | $1.75 | Oct 16, 2017 | A | 75,000 | A | — | Oct 16, 2027 | Protagenic Therapeutics, Inc. Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1Vesting in equal installments over 36 months, full vesting upon change of control